Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed 53% in the aftermath of the readout.

Altimmune (ALT) stock plunges as a Phase 2b trial for its experimental MASH therapy shows mixed results. Read more here.

Altimmune’s GLP-1/glucagon dual receptor agonist achieved a hit and a miss when it came to the dual goals of a phase 2 liver disease study.

Altimmune to Announce Topline 24 Week Results from its IMPACT Phase 2b Trial of Pemvidutide in the Treatment of MASH on Thursday, June 26 ...

Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal Pharmaceuticals moved closer to introducing the first treatment for metabolic ...

Watch Haim Mash Addison Rae’s Banger “Headphones On” Up With Janet Jackson & Joni Mitchell In BBC Live Lounge News June 23, 2025 12:33 PM By Tom Breihan ...

Objective: A high precision quantization ultrasound imaging system, capable of capturing small variances of the echo signal with a wide dynamic range, is important for producing accurate diagnostic ...